60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials

    September 2025 in “ Journal of the American Academy of Dermatology ”
    Paradi Mirmirani, Natasha Atanaskova Mesinkovska, Brett King, Maryanne M. Senna, Arash Mostaghimi, Colleen Hamilton, James V. Cassella
    TLDR Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
    The study pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials to evaluate changes in patient-reported hair satisfaction during deuruxolitinib treatment for severe alopecia areata. The trials demonstrated that patients experienced significant improvements in hair satisfaction while undergoing treatment with deuruxolitinib. This suggests that deuruxolitinib may be an effective option for enhancing hair satisfaction in individuals suffering from severe alopecia areata. The study's findings are based on comprehensive data from these two significant clinical trials.
    Discuss this study in the Community →